Current Heart Failure Reports

, Volume 7, Issue 4, pp 212–218 | Cite as

Cardiac Assessment in Duchenne and Becker Muscular Dystrophies

Article

Abstract

Mutations in the dystrophin gene cause Duchenne and Becker muscular dystrophies. In addition to muscle disease, there nearly always is an associated cardiomyopathy in Duchenne or Becker muscular dystrophy. In these muscular dystrophies, the severity of cardiomyopathy and congestive heart failure may not parallel the severity of skeletal muscle disease. Loss of normal dystrophin function in the heart produces four-chamber dilation and reduction in left ventricular function that develop after the onset of muscle weakness. Arrhythmias affecting both atrial and ventricular rhythms occur and may be life threatening. The degree to which hypoventilation and pulmonary dysfunction are present also directly affect cardiac function in muscular dystrophy. Care guidelines recently were issued to outline surveillance and treatment strategies for the younger patient with Duchenne muscular dystrophy. Herein, we review those guidelines, and additionally, provide recommendations for monitoring and treating cardiac disease in the populations of advanced Duchenne and Becker muscular dystrophies.

Keywords

Cardiomyopathy Muscular dystrophy Arrhythmia Congestive heart failure Dystrophin Duchenne muscular dystrophy Becker muscular dystrophy Cardiac magnetic resonance Late gadolinium enhancement 

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Lapidos KA, Kakkar R, McNally EM: The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res 2004, 94:1023–1031.CrossRefPubMedGoogle Scholar
  2. 2.
    •• Kaspar RW, Allen HD, Ray WC, et al.: Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in Becker muscular dystrophy. Circ Cardiovasc Genet 2009, 2:544–551. This work describes regions of the dystrophin gene that portend a risk of developing cardiomyopathy.CrossRefPubMedGoogle Scholar
  3. 3.
    Bostick B, Yue Y, Long C, Duan D: Prevention of dystrophin-deficient cardiomyopathy in twenty-one-month-old carrier mice by mosaic dystrophin expression or complementary dystrophin/utrophin expression. Circ Res 2008, 102:121–130.CrossRefPubMedGoogle Scholar
  4. 4.
    •• Bushby K, Finkel R, Birnkrant DJ, et al.: Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010, 9:77–93. This paper describes the conclusions of a consensus group recommending care guidelines for patients with DMD, including cardiac care. The guidelines are oriented toward the younger patient with DMD.CrossRefPubMedGoogle Scholar
  5. 5.
    Wagner KR, Lechtzin N, Judge DP: Current treatment of adult Duchenne muscular dystrophy. Biochim Biophys Acta 2007, 1772:229–237.PubMedGoogle Scholar
  6. 6.
    Eagle M, Bourke J, Bullock R, et al.: Managing Duchenne muscular dystrophy—the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord 2007, 17:470–475.CrossRefPubMedGoogle Scholar
  7. 7.
    Nigro G, Comi LI, Politano L, Bain RJ: The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 1990, 26:271–277.CrossRefPubMedGoogle Scholar
  8. 8.
    Perloff JK, Roberts WC, de Leon AC Jr, O’Doherty D: The distinctive electrocardiogram of Duchenne’s progressive muscular dystrophy. An electrocardiographic-pathologic correlative study. Am J Med 1967, 42:179–188.CrossRefPubMedGoogle Scholar
  9. 9.
    Frankel KA, Rosser RJ: The pathology of the heart in progressive muscular dystrophy: epimyocardial fibrosis. Hum Pathol 1976, 7:375–386.CrossRefPubMedGoogle Scholar
  10. 10.
    Heymsfield SB, McNish T, Perkins JV, Felner JM: Sequence of cardiac changes in Duchenne muscular dystrophy. Am Heart J 1978, 95:283–294.CrossRefPubMedGoogle Scholar
  11. 11.
    de Kermadec JM, Bécane HM, Chénard A, et al.: Prevalence of left ventricular systolic dysfunction in Duchenne muscular dystrophy: an echocardiographic study. Am Heart J 1994, 127:618–623.CrossRefPubMedGoogle Scholar
  12. 12.
    Sasaki K, Sakata K, Kachi E, et al.: Sequential changes in cardiac structure and function in patients with Duchenne type muscular dystrophy: a two-dimensional echocardiographic study. Am Heart J 1998, 135:937–944.CrossRefPubMedGoogle Scholar
  13. 13.
    Giglio V, Pasceri V, Messano L, et al.: Ultrasound tissue characterization detects preclinical myocardial structural changes in children affected by Duchenne muscular dystrophy. J Am Coll Cardiol 2003, 42:309–316.CrossRefPubMedGoogle Scholar
  14. 14.
    Markham LW, Michelfelder EC, Border WL, et al.: Abnormalities of diastolic function precede dilated cardiomyopathy associated with Duchenne muscular dystrophy. J Am Soc Echocardiogr 2006, 19:865–871.CrossRefPubMedGoogle Scholar
  15. 15.
    Agretto A, Politano L, Bossone E, et al.: Pulsed Doppler tissue imaging in dystrophinopathic cardiomyopathy. J Am Soc Echocardiogr 2002, 15:891–899.CrossRefPubMedGoogle Scholar
  16. 16.
    Ogata H, Nakatani S, Ishikawa Y, et al.: Myocardial strain changes in Duchenne muscular dystrophy without overt cardiomyopathy. Int J Cardiol 2007, 115:190–195.CrossRefPubMedGoogle Scholar
  17. 17.
    Mertens L, Ganame J, Claus P, et al.: Early regional myocardial dysfunction in young patients with Duchenne muscular dystrophy. J Am Soc Echocardiogr 2008, 21:1049–1054.CrossRefPubMedGoogle Scholar
  18. 18.
    Giatrakos N, Kinali M, Stephens D, et al.: Cardiac tissue velocities and strain rate in the early detection of myocardial dysfunction of asymptomatic boys with Duchenne’s muscular dystrophy: relationship to clinical outcome. Heart 2006, 92:840–842.CrossRefPubMedGoogle Scholar
  19. 19.
    Bahler RC, Mohyuddin T, Finkelhor RS, Jacobs IB: Contribution of Doppler tissue imaging and myocardial performance index to assessment of left ventricular function in patients with Duchenne’s muscular dystrophy. J Am Soc Echocardiogr 2005, 18:666–673.CrossRefPubMedGoogle Scholar
  20. 20.
    Puchalski MD, Williams RV, Askovich B, et al.: Late gadolinium enhancement: precursor to cardiomyopathy in Duchenne muscular dystrophy? Int J Cardiovasc Imaging 2009, 25:57–63.CrossRefPubMedGoogle Scholar
  21. 21.
    Silva MC, Meira ZM, Gurgel Giannetti J, et al.: Myocardial delayed enhancement by magnetic resonance imaging in patients with muscular dystrophy. J Am Coll Cardiol 2007, 49:1874–1879.CrossRefPubMedGoogle Scholar
  22. 22.
    Duboc D, Meune C, Lerebours G, et al.: Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005, 45:855–857.CrossRefPubMedGoogle Scholar
  23. 23.
    Duboc D, Meune C, Pierre B, et al.: Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years’ follow-up. Am Heart J 2007, 154:596–602.CrossRefPubMedGoogle Scholar
  24. 24.
    •• Cohn RD, van Erp C, Habashi JP, et al.: Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007, 13:204–210. (Published erratum appears in Nat Med 2007, 13:511.) This paper describes the use of ARBs in animal models of myopathy, including the mdx mouse.CrossRefPubMedGoogle Scholar
  25. 25.
    Hunt SA: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005, 46:e1–e82. (Published erratum appears in J Am Coll Cardiol 2006, 47:1503–1505.)CrossRefPubMedGoogle Scholar
  26. 26.
    Ishikawa Y, Bach JR, Minami R: Cardioprotection for Duchenne’s muscular dystrophy. Am Heart J 1999, 137:895–902.CrossRefPubMedGoogle Scholar
  27. 27.
    Jefferies JL, Eidem BW, Belmont JW, et al.: Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation 2005, 112:2799–2804.CrossRefPubMedGoogle Scholar
  28. 28.
    Ogata H, Ishikawa Y, Minami R: Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy. J Cardiol 2009, 53:72–78.CrossRefPubMedGoogle Scholar
  29. 29.
    Shaddy RE, Boucek MM, Hsu DT, et al.: Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007, 298:1171–1179.CrossRefPubMedGoogle Scholar
  30. 30.
    Viollet L, Gailey S, Thornton DJ, et al.: Utility of cystatin C to monitor renal function in Duchenne muscular dystrophy. Muscle Nerve 2009, 40:438–442.CrossRefPubMedGoogle Scholar
  31. 31.
    Bauer R, Straub V, Blain A, et al.: Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy. Eur J Heart Fail 2009, 11:463–471.CrossRefPubMedGoogle Scholar
  32. 32.
    Birnkrant DJ: The American College of Chest Physicians consensus statement on the respiratory and related management of patients with Duchenne muscular dystrophy undergoing anesthesia or sedation. Pediatrics 2009, 123(Suppl 4):S242–S244.CrossRefPubMedGoogle Scholar
  33. 33.
    •• Connuck DM, Sleeper LA, Colan SD, et al.: Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J 2008, 155:998–1005. This paper describes the outcomes from the multicenter pediatric cardiomyopathy registry. A subset of patients with dystrophin mutations describes how the patient with DMD or BMD fares compared to other pediatric cardiomyopathy patients.CrossRefPubMedGoogle Scholar
  34. 34.
    Wu RS, Gupta S, Brown RN, et al.: Clinical outcomes after cardiac transplantation in muscular dystrophy patients. J Heart Lung Transplant 2010, 29:432–438.CrossRefPubMedGoogle Scholar
  35. 35.
    Finder JD, Birnkrant D, Carl J, et al.: Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med 2004, 170:456–465.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Section of Cardiology, Department of MedicineThe University of ChicagoChicagoUSA

Personalised recommendations